• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.罗马尼亚乳腺癌和卵巢癌患者中 BRCA1/2 基因突变谱。
Int J Environ Res Public Health. 2022 Apr 4;19(7):4314. doi: 10.3390/ijerph19074314.
2
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.对罗马尼亚东北部地区乳腺癌和卵巢癌高危家族进行完整的 BRCA 基因突变筛查。
Fam Cancer. 2010 Dec;9(4):519-23. doi: 10.1007/s10689-010-9361-6.
3
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.在阿拉伯裔乳腺癌和卵巢癌患者中,BRCA1 和 BRCA2 种系突变的高发率。
Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2.
4
Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.BRCA1 和 BRCA2 种系变异在中国客家乳腺癌和卵巢癌患者中的分析。
BMC Cancer. 2022 Aug 2;22(1):842. doi: 10.1186/s12885-022-09943-0.
5
Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.乳腺癌/卵巢癌患者中新型及复发性BRCA1/BRCA2种系突变:来自突尼斯南部的系列研究
J Transl Med. 2021 Mar 16;19(1):108. doi: 10.1186/s12967-021-02772-y.
6
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.BRCA1 和 BRCA2 未分类变异体及错义多态性在阿尔及利亚乳腺癌/卵巢癌家族中的研究。
Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.
7
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.在捷克共和国,高危先证者或有乳腺癌或卵巢癌先证者的 BRCA 基因和其他候选基因的突变频率。
Mol Biol Rep. 2020 Apr;47(4):2763-2769. doi: 10.1007/s11033-020-05378-7. Epub 2020 Mar 16.
8
Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.摩洛哥北部地区乳腺癌家系中 BRCA1 c.5309G>T 及 BRCA2 c.1310_1313delAAGA 频发突变:地理特异性证据及对遗传咨询的高度相关性。
BMC Cancer. 2023 Apr 13;23(1):339. doi: 10.1186/s12885-023-10822-5.
9
Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.BRCA1/2 基因突变谱在摩洛哥遗传性乳腺癌和/或卵巢癌患者中的研究,以及中东和北非地区 BRCA 突变的研究综述。
Breast Cancer Res Treat. 2022 Jul;194(1):187-198. doi: 10.1007/s10549-022-06622-3. Epub 2022 May 17.
10
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.高危捷克乳腺癌和/或卵巢癌患者中BRCA1和BRCA2有害突变的谱系及特征分析
BMC Cancer. 2008 May 20;8:140. doi: 10.1186/1471-2407-8-140.

引用本文的文献

1
Contralateral breast cancer in patients carrying mutations in the BRCA1∕2 gene.携带BRCA1∕2基因突变的患者发生的对侧乳腺癌。
Rom J Morphol Embryol. 2025 Jan-Mar;66(1):111-118. doi: 10.47162/RJME.66.1.10.
2
Clinically Significant and Germline Variants in Breast Cancer-A Single-Center Experience.乳腺癌中具有临床意义的胚系变异——单中心经验
Cancers (Basel). 2024 Dec 26;17(1):39. doi: 10.3390/cancers17010039.
3
Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib.BRCA1 突变晚期卵巢癌的长期生存:揭示奥拉帕利的影响
Diagnostics (Basel). 2024 Aug 29;14(17):1898. doi: 10.3390/diagnostics14171898.
4
Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer-A Single-Center Experience.探索HER2阳性乳腺癌患者的治疗挑战——单中心经验
Life (Basel). 2024 Aug 18;14(8):1025. doi: 10.3390/life14081025.
5
The Molecular Detection of Germline Mutations in the and Genes Associated with Breast and Ovarian Cancer in a Romanian Cohort of 616 Patients.罗马尼亚616例患者队列中与乳腺癌和卵巢癌相关的BRCA1和BRCA2基因种系突变的分子检测
Curr Issues Mol Biol. 2024 May 12;46(5):4630-4645. doi: 10.3390/cimb46050281.
6
Clinico-genomic findings, molecular docking, and mutational spectrum in an understudied population with breast cancer patients from KP, Pakistan.来自巴基斯坦开伯尔的乳腺癌患者这一研究较少人群的临床基因组学发现、分子对接及突变谱。
Front Genet. 2024 May 9;15:1383284. doi: 10.3389/fgene.2024.1383284. eCollection 2024.
7
Preliminary insights on the mutational spectrum of BRCA1 and BRCA2 genes in Pakhtun ethnicity breast cancer patients from Khyber Pakhtunkhwa (KP), Pakistan.巴基斯坦开伯尔-普赫图赫瓦省(KP)帕克蒂亚族群乳腺癌患者中 BRCA1 和 BRCA2 基因的突变谱的初步见解。
Neoplasia. 2024 May;51:100989. doi: 10.1016/j.neo.2024.100989. Epub 2024 Mar 27.
8
Hereditary Breast Cancer in Romania-Molecular Particularities and Genetic Counseling Challenges in an Eastern European Country.罗马尼亚的遗传性乳腺癌——一个东欧国家的分子特征与遗传咨询挑战
Biomedicines. 2023 May 8;11(5):1386. doi: 10.3390/biomedicines11051386.
9
Spectrum of High-Risk Mutations among Breast Cancer Patients Referred for Multigene Panel Testing in a Romanian Population.罗马尼亚人群中接受多基因检测的乳腺癌患者的高风险突变谱。
Cancers (Basel). 2023 Mar 22;15(6):1895. doi: 10.3390/cancers15061895.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.土耳其特拉基亚地区高危 BRCA 相关乳腺癌/卵巢癌个体的遗传筛查结果。
J BUON. 2020 May-Jun;25(3):1337-1347.
3
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.保加利亚高危乳腺癌患者中BRCA1/2基因突变的谱系和频率
BMC Cancer. 2015 Jul 17;15:523. doi: 10.1186/s12885-015-1516-2.
4
The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.韩国人群中BRCA1和BRCA2突变的患病率及谱系:韩国遗传性乳腺癌(KOHBRA)研究的最新进展
Breast Cancer Res Treat. 2015 May;151(1):157-68. doi: 10.1007/s10549-015-3377-4. Epub 2015 Apr 12.
5
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.BRCA1和BRCA2基因复发性突变在墨西哥具有显著的临床影响。
Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.
6
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.全面聚焦乳腺癌中BRCA1和BRCA2突变的全球谱系。
Biomed Res Int. 2013;2013:928562. doi: 10.1155/2013/928562. Epub 2013 Nov 7.
7
Hereditary breast and ovarian cancer susceptibility genes (review).遗传性乳腺癌和卵巢癌易感基因(综述)。
Oncol Rep. 2013 Sep;30(3):1019-29. doi: 10.3892/or.2013.2541. Epub 2013 Jun 19.
8
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.BRCA1 和 BRCA2 突变携带者的癌症风险:EMBRACE 前瞻性分析的结果。
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
9
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.欧洲发现 BRCA1/2 基因突变:对遗传性乳腺癌-卵巢癌预防和控制的影响。
EPMA J. 2010 Sep;1(3):397-412. doi: 10.1007/s13167-010-0037-y. Epub 2010 Jun 27.
10
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry.非洲裔乳腺癌患者中 BRCA1 和 BRCA2 基因突变的复发性。
Breast Cancer Res Treat. 2012 Jul;134(2):889-94. doi: 10.1007/s10549-012-2136-z. Epub 2012 Jun 28.

罗马尼亚乳腺癌和卵巢癌患者中 BRCA1/2 基因突变谱。

Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.

机构信息

Oncology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

The Oncology Institute "Ion Chiricuta", Republicii Street, No 34-36, 400015 Cluj-Napoca, Romania.

出版信息

Int J Environ Res Public Health. 2022 Apr 4;19(7):4314. doi: 10.3390/ijerph19074314.

DOI:10.3390/ijerph19074314
PMID:35409996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8998351/
Abstract

Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients at high risk of inherited breast and ovarian cancer. Methods: We evaluated 250 women of Romanian ethnicity with BC and 240 women of Romanian ethnicity with ovarian cancer for the presence of damaging germline mutations in breast cancer genes 1 and 2 (BRCA1 and BRCA2, respectively) using Next-Generation Sequencing (NGS) technology. Results: Of the 250 breast cancer patients, 47 carried a disease-predisposing BRCA mutation (30 patients (63.83%) with a BRCA1 mutation and 17 patients (36.17%) with a BRCA2 mutation). Of the 240 ovarian cancer patients, 60 carried a BRCA mutation (43 patients (72%) with a BRCA1 mutation and 17 patients (28%) with a BRCA2 mutation). In the BRCA1 gene, we identified 18 variants (4 in both patient groups (ovarian and breast cancer patients), 1 mutation variant in the BC patient group, and 13 mutation variants in the ovarian cancer patient group). In the BRCA2 gene, we identified 17 variants (1 variant in both ovarian and breast cancer patients, 6 distinct variants in BC patients, and 10 distinct variants in ovarian cancer patients). The prevailing mutation variants identified were c.3607C>T (BRCA1) (18 cases) followed by c.5266dupC (BRCA1) (17 cases) and c.9371A>T (BRCA2) (12 cases). The most prevalent mutation, BRCA1 c.3607C>T, which is less common in the Romanian population, was mainly associated with triple-negative BC and ovarian serous adenocarcinoma. Conclusion: The results of our analysis may help to establish specific variants of BRCA mutations in the Romanian population and identify individuals at high risk of hereditary breast and ovarian cancer syndrome by genetic testing.

摘要

背景

在罗马尼亚,每年约有 10000 名女性被诊断患有乳腺癌,约 2000 名女性被诊断患有卵巢癌。罗马尼亚人群中进行的遗传研究数量不足,无法识别遗传性乳腺癌和卵巢癌的高危患者。方法:我们使用下一代测序(NGS)技术,对 250 名罗马尼亚裔乳腺癌患者和 240 名罗马尼亚裔卵巢癌患者进行了乳腺癌基因 1 和 2(BRCA1 和 BRCA2)种系致病变异的检测。结果:在 250 名乳腺癌患者中,47 名患者携带疾病易感性 BRCA 突变(30 名患者(63.83%)存在 BRCA1 突变,17 名患者(36.17%)存在 BRCA2 突变)。在 240 名卵巢癌患者中,60 名患者携带 BRCA 突变(43 名患者(72%)存在 BRCA1 突变,17 名患者(28%)存在 BRCA2 突变)。在 BRCA1 基因中,我们发现了 18 个变异(在卵巢癌和乳腺癌患者组中各有 4 个,在乳腺癌患者组中有 1 个突变变异,在卵巢癌患者组中有 13 个突变变异)。在 BRCA2 基因中,我们发现了 17 个变异(在卵巢癌和乳腺癌患者组中各有 1 个,在乳腺癌患者组中有 6 个不同的变异,在卵巢癌患者组中有 10 个不同的变异)。最常见的突变变异是 c.3607C>T(BRCA1)(18 例),其次是 c.5266dupC(BRCA1)(17 例)和 c.9371A>T(BRCA2)(12 例)。在罗马尼亚人群中较少见的 BRCA1 c.3607C>T 主要与三阴性乳腺癌和卵巢浆液性腺癌相关。结论:我们的分析结果有助于确定罗马尼亚人群中 BRCA 突变的具体变体,并通过基因检测识别遗传性乳腺癌和卵巢癌综合征的高危个体。